An observational study in Bone Disorder, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged Up to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by University Hospital, Toulouse · Observational
The aim of this project is to set up a biological and clinical collection of patients with progressive bone, calcium and growth plate pathologies.
This collection will provide a better understanding of the mechanisms involved in growth plate and bone damage in these diseases and identify factors predictive of progression and new therapeutic targets.
177 studies on the registry are indexed under Bone Diseases; 38 are open to participants now.
This study's planned enrollment of 350 is above the median of 150 across 55 observational studies indexed under Bone Diseases.
Browse Bone Diseases studies →University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with with growth plate or bone pathology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
As part of their pathology, patients benefit from clinical monitoring and regular blood and urine tests.
Other: Biological samples · Other: Biological
Blood and urine will be taken in larger quantity
Surgical residues may be preserved in the event of surgery carried out as part of the treatment.
Building a collection of biological samples and clinical-biological data from patients presenting bone, calcium and growth plate pathologies
Blood and urine sampling
Time frame: Day 0 and through study completion, an average of 5 years
Identification of potential markers of disease progression based on new knowledge.
Time frame: Day 0 and through study completion, an average of 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2034, 120 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →